Drug Manufacturers - Specialty & Generic
Compare Stocks
3 / 10Stock Comparison
YCBD vs TLRY vs CGC
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
YCBD vs TLRY vs CGC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $8M | $660M | $122M |
| Revenue (TTM) | $19M | $1.17B | $294M |
| Net Income (TTM) | $-328M | $-2.95B | $-327M |
| Gross Margin | 59.8% | 28.0% | 22.8% |
| Operating Margin | -5.7% | -266.0% | -24.1% |
| Total Debt | $778M | $451M | $348M |
| Cash & Equiv. | $2M | $304M | $114M |
YCBD vs TLRY vs CGC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| cbdMD, Inc. (YCBD) | 100 | 0.2 | -99.8% |
| Tilray Brands, Inc. (TLRY) | 100 | 57.5 | -42.5% |
| Canopy Growth Corpo… (CGC) | 100 | 0.7 | -99.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: YCBD vs TLRY vs CGC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
YCBD has the current edge in this matchup, primarily because of its strength in income & stability.
- Dividend streak 0 yrs, beta 0.66
- -6.5% margin vs TLRY's -252.6%
- Beta 0.66 vs TLRY's 2.03
TLRY is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 4.8%, EPS growth -6.5%, 3Y rev CAGR 12.5%
- -74.7% 10Y total return vs CGC's -94.3%
- 4.8% revenue growth vs CGC's -9.5%
CGC is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.90, Low D/E 71.5%, current ratio 3.12x
- Beta 1.90, current ratio 3.12x
- -29.5% ROA vs YCBD's -27.8%, ROIC -10.2% vs -0.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 4.8% revenue growth vs CGC's -9.5% | |
| Quality / Margins | -6.5% margin vs TLRY's -252.6% | |
| Stability / Safety | Beta 0.66 vs TLRY's 2.03 | |
| Dividends | Tie | None of these 3 stocks pay a meaningful dividend |
| Momentum (1Y) | +12.1% vs CGC's -12.4% | |
| Efficiency (ROA) | -29.5% ROA vs YCBD's -27.8%, ROIC -10.2% vs -0.4% |
YCBD vs TLRY vs CGC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
YCBD vs TLRY vs CGC — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
YCBD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TLRY is the larger business by revenue, generating $1.2B annually — 62.2x YCBD's $19M. Profitability is closely matched — net margins range from -6.5% (YCBD) to -2.5% (TLRY). On growth, YCBD holds the edge at +980.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $19M | $1.2B | $294M |
| EBITDAEarnings before interest/tax | -$286M | -$3.0B | -$32M |
| Net IncomeAfter-tax profit | -$328M | -$2.9B | -$327M |
| Free Cash FlowCash after capex | -$853M | -$94M | -$86M |
| Gross MarginGross profit ÷ Revenue | +59.8% | +28.0% | +22.8% |
| Operating MarginEBIT ÷ Revenue | -5.7% | -2.7% | -24.1% |
| Net MarginNet income ÷ Revenue | -6.5% | -2.5% | -111.0% |
| FCF MarginFCF ÷ Revenue | -16.9% | -8.1% | -29.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +980.1% | +3.0% | +20.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +83.6% | +70.7% | +83.8% |
Valuation Metrics
YCBD leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $8M | $660M | $122M |
| Enterprise ValueMkt cap + debt − cash | $784M | $806M | $293M |
| Trailing P/EPrice ÷ TTM EPS | -0.76x | -0.17x | -0.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.44x | 0.59x | 0.62x |
| Price / BookPrice ÷ Book value/share | 0.46x | 0.25x | 0.34x |
| Price / FCFMarket cap ÷ FCF | — | — | — |
Profitability & Efficiency
CGC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
YCBD delivers a -3.6% return on equity — every $100 of shareholder capital generates $-4 in annual profit, vs $-137 for TLRY. TLRY carries lower financial leverage with a 0.22x debt-to-equity ratio, signaling a more conservative balance sheet compared to YCBD's 107.70x. On the Piotroski fundamental quality scale (0–9), YCBD scores 5/9 vs TLRY's 4/9, reflecting solid financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -3.6% | -136.5% | -43.1% |
| ROA (TTM)Return on assets | -27.8% | -100.6% | -29.5% |
| ROICReturn on invested capital | -0.4% | -66.2% | -10.2% |
| ROCEReturn on capital employed | -47.1% | -78.1% | -12.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 5 |
| Debt / EquityFinancial leverage | 107.70x | 0.22x | 0.72x |
| Net DebtTotal debt minus cash | $776M | $147M | $235M |
| Cash & Equiv.Liquid assets | $2M | $304M | $114M |
| Total DebtShort + long-term debt | $778M | $451M | $348M |
| Interest CoverageEBIT ÷ Interest expense | — | -89.43x | -7.79x |
Total Returns (Dividends Reinvested)
TLRY leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TLRY five years ago would be worth $3,498 today (with dividends reinvested), compared to $6 for YCBD. Over the past 12 months, TLRY leads with a +1209.3% total return vs CGC's -12.4%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.7% vs YCBD's -63.0% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -28.4% | -41.8% | -5.0% |
| 1-Year ReturnPast 12 months | -8.8% | +1209.3% | -12.4% |
| 3-Year ReturnCumulative with dividends | -94.9% | +103.6% | -91.4% |
| 5-Year ReturnCumulative with dividends | -99.9% | -65.0% | -99.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | -74.7% | -94.3% |
| CAGR (3Y)Annualised 3-year return | -63.0% | +26.7% | -55.9% |
Risk & Volatility
Evenly matched — YCBD and CGC each lead in 1 of 2 comparable metrics.
Risk & Volatility
YCBD is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CGC currently trades 47.5% from its 52-week high vs YCBD's 32.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.66x | 2.03x | 1.90x |
| 52-Week HighHighest price in past year | $2.56 | $15.70 | $2.38 |
| 52-Week LowLowest price in past year | $0.47 | $0.35 | $0.84 |
| % of 52W HighCurrent price vs 52-week peak | +32.4% | +36.1% | +47.5% |
| RSI (14)Momentum oscillator 0–100 | 58.0 | 37.9 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 4.7M | 10.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: TLRY as "Hold", CGC as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs 76.7% for TLRY (target: $10).
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold |
| Price TargetConsensus 12-month target | — | $10.00 | $14.47 |
| # AnalystsCovering analysts | — | 20 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% |
YCBD leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). CGC leads in 1 (Profitability & Efficiency). 1 tied.
YCBD vs TLRY vs CGC: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is YCBD or TLRY or CGC a better buy right now?
For growth investors, Tilray Brands, Inc.
(TLRY) is the stronger pick with 4. 8% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Analysts rate Tilray Brands, Inc. (TLRY) a "Hold" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — YCBD or TLRY or CGC?
Over the past 5 years, Tilray Brands, Inc.
(TLRY) delivered a total return of -65. 0%, compared to -99. 9% for cbdMD, Inc. (YCBD). Over 10 years, the gap is even starker: TLRY returned -74. 7% versus YCBD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — YCBD or TLRY or CGC?
By beta (market sensitivity over 5 years), cbdMD, Inc.
(YCBD) is the lower-risk stock at 0. 66β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 206% more volatile than YCBD relative to the S&P 500. On balance sheet safety, Tilray Brands, Inc. (TLRY) carries a lower debt/equity ratio of 22% versus 108% for cbdMD, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — YCBD or TLRY or CGC?
By revenue growth (latest reported year), Tilray Brands, Inc.
(TLRY) is pulling ahead at 4. 8% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: cbdMD, Inc. grew EPS 39. 1% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, TLRY leads at 12. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — YCBD or TLRY or CGC?
cbdMD, Inc.
(YCBD) is the more profitable company, earning -10. 6% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps -10. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: YCBD leads at -11. 3% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — YCBD leads at 56. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — YCBD or TLRY or CGC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is YCBD or TLRY or CGC better for a retirement portfolio?
For long-horizon retirement investors, cbdMD, Inc.
(YCBD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66)). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YCBD: -100. 0%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between YCBD and TLRY and CGC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.